% | $
Quotes you view appear here for quick access.


  • keep_investing keep_investing May 17, 2014 11:06 AM Flag

    Dr lanza and his teams creative breakthrough's in ESC uses....

    ....are the reasons for owning this stock. And with the projection of over 200M people world wide having AMD by 2020, which could translate into a one trillion dollar market, which makes hanging onto to stock a must, no matter how mum & dumb management has become.
    Below is the latest breakthrough by Dr lanza and his team of scientists:
    "Mesenchymal stem cells (MSCs) are being tested in a wide range of human diseases; however, loss of potency and inconsistent quality severely limit their use. To overcome these issues, we have utilized a developmental precursor called the hemangioblast as an intermediate cell type in the derivation of a highly potent and replenishable population of MSCs from human embryonic stem cells (hESCs). This method circumvents the need for labor-intensive hand-picking, scraping, and sorting that other hESC-MSC derivation methods require. Moreover, unlike previous reports on hESC-MSCs, we have systematically evaluated their immunomodulatory properties and in vivo potency. As expected, they dynamically secrete a range of bioactive factors, display enzymatic activity, and suppress T-cell proliferation that is induced by either allogeneic cells or mitogenic stimuli. However, they also display unique immunophenotypic properties, as well as a smaller size and 30,000-fold proliferative capacity than bone marrow-derived MSCs. In addition, this is the first report which demonstrates that hESC-MSCs can inhibit CD83 up-regulation and IL-12p70 secretion from dendritic cells and enhance regulatory T-cell populations induced by interleukin 2 (IL-2). This is also the first report which shows that hESC-MSCs have therapeutic efficacy in two different autoimmune disorder models, including a marked increase in survival of lupus-prone mice and a reduction of symptoms in an autoimmune model of uveitis."

    SortNewest  |  Oldest  |  Most Replied Expand all replies